Safety and Traceability in the Wake of GE Healthcare's FBS Recall- An interview with Rosemary Versteegen

Add bookmark

Safety and Traceability in the Wake of GE Healthcare's FBS Recall- An interview with Rosemary Versteegen

Add bookmark
When GE Healthcare recently withdrew their Fetal Bovine Serum (FBS) products due to non-conformancies, it highlighted the real need for product safety and traceability practices in the field. Pharma IQ spoke to Rosemary Versteegen, CEO of the International Serum Industry Association about this case and what the industry can learn from it. [inlinead]

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended